[Experience of Teraligen usage in pediatric psychiatry]. / Opyt primeneniya Teralidzhena v psikhiatrii detskogo vozrasta.

The data of studies on the use of Teraligen in various fields of clinical medicine - neurology, dermatology, gastroenterology, anesthesiology and psychiatry are presented. According to studies conducted in psychiatry, Teraligen is a drug for the balanced treatment of anxiety-phobic, behavioral and sleep disorders in children, both within neurotic conditions and in the structure of autistic and schizophrenic spectrum disorders. Based on 100 case histories of children aged 3 to 16 years, the experience of using Teraligen as part of mono- and combination therapy at a dosage of 1.25 mg to 50 mg/day in the treatment of autism spectrum disorders (n=31), psychotic disorders (n=18), schizotypal disorders (n=41), behavioral and emotional disorders on residual organic soil (n=10). A good clinical effect of Teraligen has been shown in anxiety-phobic, affective, somatovegetative disorders and sleep disorders in all identified nosologies. Good tolerability of Teraligen, the possibility of its use as part of complex therapy and the almost complete absence of adverse events, indicating the softness and balance of the drug were noted.

[The first episode of psychosis in juvenile patients: personality features and cognitive functioning].

A systemic study of personality features and cognitive processes based on the conception of pathopsychological syndrome has been conducted in patients with the first episode of juvenile endogenous psychosis. The association between characteristics of a pathopsychological syndrome and clinically determined premorbid features has been identified. The highest expression of schizotypal features (reduced selectivity, social perception) and cognitive impairment (motivation, mental activity regulation, adequate self-esteem, emotional reaction to success/failure) were characteristic of a group named "deficit variant of pseudopsychopathy" which contained a large number of passive schizoids. It has been shown that premorbid personality features are most distinct in initial stages of disease ("pathos" factors). "Nosos" factors are implicit and can be only presumably regarded as predictors of disease course.